NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Mar 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
5/8 — Partial
Priority Review
PHENYLEPHRINE HYDROCHLORIDE (phenylephrine hydrochloride) by Aspiro Therapeutics is alpha-1 adrenergic receptor agonist used for dilation of the pupil due to its vasoconstrictor and mydriatic action. Approved for nasal congestion, seasonal allergic rhinitis, vasomotor rhinitis and 4 more indications. First approved in 2013.
Drug data last refreshed 20h ago
Mechanism of Action
alpha-1 adrenergic receptor agonist used for dilation of the pupil due to its vasoconstrictor and mydriatic action. Phenylephrine possesses predominantly α-adrenergic effects. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic, by constricting ophthalmic blood vessels…
Indications (7)
Worked on PHENYLEPHRINE HYDROCHLORIDE at Aspiro Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.